Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jul;178(1):99-105.
doi: 10.1111/bjh.14647. Epub 2017 Apr 7.

CD49d associates with nodal presentation and subsequent development of lymphadenopathy in patients with chronic lymphocytic leukaemia

Paolo Strati  1 , Sameer A Parikh  1 , Kari G Chaffee  1 , Sara J Achenbach  1 , Susan L Slager  1 , Timothy G Call  1 , Wei Ding  1 , Diane F Jelinek  1 , Curtis A Hanson  1 , Neil E Kay  1 , Tait D Shanafelt  1
Affiliations

CD49d associates with nodal presentation and subsequent development of lymphadenopathy in patients with chronic lymphocytic leukaemia

Paolo Strati et al. Br J Haematol. 2017 Jul.

Abstract

CD49d is a surface integrin that is expressed on chronic lymphocytic leukaemia (CLL) cells, and strongly correlates with more aggressive disease. Given its association with cell-cell adhesion and leucocyte trafficking, we hypothesized that patients with high CD49d expression would experience a clinical course dominated by lymphadenopathy. CD49d expression was measured by flow cytometry and considered positive if expressed by ≥30% of CLL cells. The study included 797 newly diagnosed CLL/small lymphocytic leukaemia patients; 279 (35%) were CD49d positive. CD49d-positive patients were more likely to present with lymphadenopathy (P < 0·001); a finding that persisted after adjusting for fluorescence in situ hybridisation (FISH) and IGHV mutation status [odds ratio (OR) 2·51; 95% confidence interval (CI) 1·64-3·83; P < 0·001]. Among CLL Rai 0 patients, CD49d positivity was associated with shorter time to development of lymphadenopathy (3·2 years vs not reached, P < 0·01). This association was maintained after adjusting for either FISH [hazard ratio (HR) 2·18; 95% CI 1·25-3·81; P = 0·006) or IGHV status (HR 2·02; 95% CI 1·11-3·69; P = 0·02) individually, but was attenuated when adjusting by both (HR 1·72; 95% CI 0·88-3·38; P = 0·11).These data demonstrate that CD49d-positive CLL patients experience a disease course dominated by lymphadenopathy. These findings could have implications for therapy selection and disease monitoring.

Keywords: CD49d; chronic lymphocytic leukaemia; lymphadenopathy; small lymphocytic lymphoma.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest

The other authors declare no conflicts of interest.

Figures

Fig 1
Fig 1
Association between CD49d expression at time of diagnosis and type of CLL presentation. The percentage of lymphocytes expressing CD49d is shown on the y-axis (each bar shows median, first, and third quartiles). (A) By Rai stage; (B) By lymphadenopathy. CLL, chronic lymphocytic leukaemia; LN, lymphadenopathy; SLL, small lymphocytic leukaemia; w/o, without.
Fig 2
Fig 2
Time from diagnosis to lymphadenopathy development by CD49d negative (<30% expression), CD49d positive (>30% expression) among newly diagnosed chronic lymphocytic leukaemia patients presenting with Rai stage 0 disease.
See this image and copyright information in PMC

References

    1. Aydin S, Grabellus F, Eisele L, Mollmann M, Hanoun M, Ebeling P, Moritz T, Carpinteiro A, Nuckel H, Sak A, Gothert JR, Duhrsen U, Durig J. Investigating the role of CD38 and functionally related molecular risk factors in the CLL NOD/SCID xenograft model. European Journal of Haematology. 2011;87:10–19. - PubMed
    1. Bairey O, Zimra Y, Rabizadeh E, Shaklai M. Expression of adhesion molecules on leukemic B cells from chronic lymphocytic leukemia patients with predominantly splenic manifestations. The Israel Medical Association Journal: IMAJ. 2004;6:147–151. - PubMed
    1. Bomben R, Dal Bo M, Capello D, Benedetti D, Marconi D, Zucchetto A, Forconi F, Maffei R, Ghia EM, Laurenti L, Bulian P, Del Principe MI, Palermo G, Thorselius M, Degan M, Campanini R, Guarini A, Del Poeta G, Rosenquist R, Efremov DG, Marasca R, Foa R, Gaidano G, Gattei V. Comprehensive characterization of IGHV3-21-expressing B-cell chronic lymphocytic leukemia: an Italian multicenter study. Blood. 2007;109:2989–2998. - PubMed
    1. Buchner M, Baer C, Prinz G, Dierks C, Burger M, Zenz T, Stilgenbauer S, Jumaa H, Veelken H, Zirlik K. Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia. Blood. 2010;115:4497–4506. - PubMed
    1. Buggins AG, Pepper C, Patten PE, Hewamana S, Gohil S, Moorhead J, Folarin N, Yallop D, Thomas NS, Mufti GJ, Fegan C, Devereux S. Interaction with vascular endothelium enhances survival in primary chronic lymphocytic leukemia cells via NF-kappaB activation and de novo gene transcription. Cancer Research. 2010;70:7523–7533. - PubMed

Publication types

MeSH terms

LinkOut - more resources